Skip to content
★ Sign in to follow
CR

China Regenerative Medicine International Ltd. Stock: price and insider trades · Hong Kong

HK·Mcap HK$77.6MHealth Care

No insider purchase over the last 90 days. The latest, by WANG CHUANG, was filed 15 Dec 2023.

China Regenerative Medicine International Ltd.: what insiders have been doing

China Regenerative Medicine International Ltd., classified in the Health Care sector, is a listed company. Its insiders report their share dealings to HKEX. The past year has been quiet: not a single insider filing for China Regenerative Medicine International Ltd. The previous disclosure was published on 15 December 2023.

The full history, which starts in 2019, counts 22 purchases against no sales.

Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and EssilorLuxottica. These figures are compiled from regulatory filings published by HKEX. They describe what insiders did and are not a recommendation.

Insider Decl.
23
Thresholds
n/a
Buy Volume
€33M
22 ops. · all time
Sell Volume
n/a
n/a

Since the insiders bought

  • Filed 15 Dec 2023 · 1059 days ago · €1.9M
    -28.0%
    Entry HK$0.59 · Close at T+365 HK$0.43
  • Filed 28 Dec 2020 · 2141 days ago · €3.5M
    -58.2%
    Entry HK$6.70 · Close at T+365 HK$2.80

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 741 of 26,897 companies
82.6
score / 100
Value
85
Quality
81
FCF yld5.2%
Earn yld35%
EV/EBITDA4.9x
ROE64%
Gross mgn58%
Net mgn38%
Debt/EBITDA2.0x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

HK$0.26
Analyst consensus
·
Income statement
RevenueHK$72.1M
Gross profitHK$41.9M58% margin
EBITDAHK$26.2M36% margin
Net incomeHK$27.5M31.9% margin
Valuation
PER (trailing)2.8x
P/Book1.4x
Beta-0.96
Balance sheet & cash
Market capHK$77.6M
Total debtHK$51.3M
Free Cash FlowHK$4M
Debt / Equity67%
Profitability & ownership
ROE64.2%
ROA3.4%
% insiders58.0%
% institutions5.2%
Last declaration on 15 December 2023
Declarations23 total
  • ▲
    DirectorExecutives
    16M HKD12HKEX
    18,823,530 shares@ HK$0.856.6% of flowShareXHKGHKEX:DA20231215E00140
    Canonical exit: 12 Mar 2024 (T+90)
  • ▲
    DirectorExecutives
    458,150 HKD11HKEX
    2,695,000 shares@ HK$0.170.2% of flowShareXHKGHKEX:DA20220916E00228
    Canonical exit: 14 Dec 2022 (T+90)
  • ▲
    DirectorExecutives
    510,972 HKD11HKEX
    3,080,000 shares@ HK$0.16590.2% of flowShareXHKGHKEX:DA20220908E00132
    Canonical exit: 6 Dec 2022 (T+90)
  • ▲
    DirectorExecutives
    511,500 HKD11HKEX
    3,100,000 shares@ HK$0.1650.2% of flowShareXHKGHKEX:DA20220906E00252
    Canonical exit: 4 Dec 2022 (T+90)
  • ▲
    DirectorExecutives
    493,850 HKD11HKEX
    2,975,000 shares@ HK$0.1660.2% of flowShareXHKGHKEX:DA20220829E00222
    Canonical exit: 24 Nov 2022 (T+90)
  • ▲
    DirectorExecutives
    113M HKD27HKEX
    265,290,000 shares@ HK$0.42541.5% of flowShareXHKGHKEX:DA20210111E00403
    Canonical exit: 8 Apr 2021 (T+90)
  • ●
    DirectorExecutives
    0HKEX
    70,950,000 sharesShareXHKGHKEX:DA20210111E00237
  • ▲
    DirectorExecutives
    303,104 HKD23HKEX
    740,000 shares@ HK$0.40960.1% of flowShareXHKGHKEX:DA20210108E00053
    Canonical exit: 7 Apr 2021 (T+90)
  • ▲
    DirectorExecutives
    33M HKD31HKEX
    48,330,000 shares@ HK$0.6985.4% of flowShareXHKGHKEX:DA20201228E00026
    Canonical exit: 24 Mar 2021 (T+90)
  • ▲
    DirectorExecutives
    76M HKD14HKEX
    140,000,000 shares@ HK$0.5428.1% of flowShareXHKGHKEX:DA20201214E00330
    Canonical exit: 14 Mar 2021 (T+90)
  • ▲
    DirectorExecutives
    55M HKD13HKEX
    107,500,000 shares@ HK$0.5120.5% of flowShareXHKGHKEX:DA20201211E00380
    Canonical exit: 10 Mar 2021 (T+90)
  • ▲
    DirectorExecutives
    250,000 HKD23HKEX
    1,000,000 shares@ HK$0.250.7% of flowShareXHKGHKEX:DA20191211E00282
    Canonical exit: 10 Mar 2020 (T+90)
  • ▲
    DirectorExecutives
    166,800 HKD23HKEX
    695,000 shares@ HK$0.240.5% of flowShareXHKGHKEX:DA20191209E00136
    Canonical exit: 5 Mar 2020 (T+90)
  • ▲
    DirectorExecutives
    587,482 HKD23HKEX
    2,455,000 shares@ HK$0.23930.2% of flowShareXHKGHKEX:DA20191209E00129
    Canonical exit: 4 Mar 2020 (T+90)
  • ▲
    DirectorExecutives
    271,152 HKD23HKEX
    1,135,000 shares@ HK$0.23890.1% of flowShareXHKGHKEX:DA20191209E00128
    Canonical exit: 3 Mar 2020 (T+90)
  • ▲
    DirectorExecutives
    7,179 HKD23HKEX
    30,000 shares@ HK$0.23930.0% of flowShareXHKGHKEX:DA20191205E00357
    Canonical exit: 4 Mar 2020 (T+90)
  • ▲
    DirectorExecutives
    414,816 HKD23HKEX
    1,740,000 shares@ HK$0.23840.2% of flowShareXHKGHKEX:DA20191204E00308
    Canonical exit: 2 Mar 2020 (T+90)
  • ▲
    DirectorExecutives
    400,106 HKD23HKEX
    1,795,000 shares@ HK$0.22291.1% of flowShareXHKGHKEX:DA20191204E00075
    Canonical exit: 2 Mar 2020 (T+90)
  • ▲
    DirectorExecutives
    1M HKD23HKEX
    4,560,000 shares@ HK$0.22210.4% of flowShareXHKGHKEX:DA20191203E00070
    Canonical exit: 1 Mar 2020 (T+90)
  • ▲
    DirectorExecutives
    612,700 HKD23HKEX
    2,750,000 shares@ HK$0.22281.7% of flowShareXHKGHKEX:DA20191202E00260
    Canonical exit: 1 Mar 2020 (T+90)
  • ▲
    DirectorExecutives
    2M HKD24HKEX
    8,500,000 shares@ HK$0.2235.3% of flowShareXHKGHKEX:DA20191129E00280
    Canonical exit: 27 Feb 2020 (T+90)
  • ▲
    DirectorExecutives
    3M HKD23HKEX
    15,250,000 shares@ HK$0.22091.4% of flowShareXHKGHKEX:DA20191129E00307
    Canonical exit: 27 Feb 2020 (T+90)
  • ▲
    DirectorExecutives
    2M HKD12HKEX
    7,850,000 shares@ HK$0.24125.3% of flowShareXHKGHKEX:DA20191128E00350
    Canonical exit: 26 Feb 2020 (T+90)

23 of 23 declarations

About China Regenerative Medicine International Ltd.

China Regenerative Medicine International Ltd. is a company focused on the development and commercialization of regenerative medicine products. It is listed on the Hong Kong Stock Exchange under the symbol XHKG.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations